Ameriprise
BLTE

Ameriprise’s Belite Bio BLTE Stock Holding History

Ameriprise’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$441K Sell
2,767
-10,454
-79% -$1.76M ﹤0.01% 3635
2025
Q4 		$2.11M Buy
13,221
+10,190
+336% +$1.21M ﹤0.01% 2970
2025
Q3 		$224K Buy
+3,031
New +$199K ﹤0.01% 3879
2025
Q2 		– Sell
-3,075
Closed -$204K – 3982
2025
Q1 		$204K Buy
+3,075
New +$185K ﹤0.01% 3792

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise's BLTE Position: Q1 2026 in Review

Ameriprise reduced its Belite Bio (BLTE) stake by 79% in Q1 2026, selling an estimated $1.76M and leaving 2,767 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #3635.

Ameriprise first reported a position in BLTE in Q1 2025 and has held it in 4 quarters since. The position peaked at $2.11M in Q4 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Ameriprise held 2,767 shares of Belite Bio worth $441K as of Q1 2026.
  • Ameriprise sold 10,454 Belite Bio shares in Q1 2026, an estimated $1.76M.
  • Belite Bio made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3635 holding.
  • Ameriprise first reported a position in Belite Bio in Q1 2025 and has held it in 4 quarters since.
  • Ameriprise's Belite Bio position peaked at $2.11M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.